

Hopf, N.B.; Ruder, A.; Waters, M.A.; Succop, P. **Concentration-dependent half-lives of polychlorinated biphenyl in sera from an occupational cohort.** Chemosphere, 91(2):172-178, 2013.

Postprint version	Final draft post-refereeing
Journal website	http://www.sciencedirect.com/science/journal/00456535
Pubmed link	http://www.ncbi.nlm.nih.gov/pubmed/23336921
DOI	10.1016/j.chemosphere.2012.12.039

Concentration-dependent Half-Lives of Polychlorinated Biphenyl in Sera from an Occupational Cohort

Nancy B. Hopf¹, Avima M. Ruder², Martha A. Waters², Paul Succop³

¹ Institute for Work and Health (IST), Rue du Bugnon 21, CH-1011 Lausanne, Switzerland.
Nancy.Hopf@hospvd.ch; NancyBHopf@gmail.com

² Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, Cincinnati, Ohio 45226, USA. amr2@cdc.gov; maw0@cdc.gov

³ University of Cincinnati, Department of Environmental Health, Kettering G29, PO Box 670056, Cincinnati, Ohio 45267, USA.
succopa@uc.edu

Disclaimers: Mention of company names or products does not constitute endorsement by the National Institute for Occupational Safety and Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.

Corresponding author:

Nancy B. Hopf, Ph.D.
Institute for Work and Health (IST), Rue du Bugnon 21, CH-1011 Lausanne, Switzerland
Nancy.Hopf@hospvd.ch; NancyBHopf@gmail.com

+41 (0) 21 314 9558 (voice) +41 (0) 21 314 7430 (fax)

Keywords: Polychlorinated biphenyls, PCB, half-life, serum PCB

Highlights

1. This is the largest and longest studied cohort of workers exposed to PCBs for whom serum values are available
2. We present PCB half-life estimates using sera from four time points
3. PCB half-life estimates are for two commercial PCB mixtures (Aroclor 1254 and 1242)
4. Two serum PCB elimination rates were discovered (rapid and then slow)
5. Gender differences were observed only for Aroclor 1242 in earlier years.

1
2
3
4

5
6
7

Abstract

8 Polychlorinated biphenyls (PCBs) are carcinogenic. Estimating PCB half-life in the body based
9 on levels in sera from exposed workers is complicated by the fact that occupational exposure to
10 PCBs was to commercial PCB products (such as Aroclors 1242 and 1254) comprised of varying
11 mixtures of PCB congeners. Half-lives were estimated using sera donated by 191 capacitor
12 manufacturing plant workers in 1976 during PCB use (1946-1977), and post-exposure (1979,
13 1983, and 1988). Our aims were to: (1) determine the role of covariates such as gender on the
14 half-life estimates, and (2) compare our results with other published half-life estimates based on
15 exposed workers. All serum PCB levels were adjusted for PCB background levels. A linear
16 spline model with a single knot was used to estimate two separate linear equations for the first
17 two serum draws (Equation A) and the latter two (Equation B). Equation A gave half-life
18 estimates of 1.74 years and 6.01 years for Aroclor 1242 and Aroclor 1254, respectively.
19 Estimates were 21.83 years for Aroclor 1242 and 133.33 years for Aroclor 1254 using Equation
20 B. High initial body burden was associated with rapid PCB elimination in workers at or shortly
21 after the time they were occupationally exposed and slowed down considerably when the dose
22 reached background PCB levels. These concentration-dependent half-life estimates had a
23 transition-point of 138.57 and 34.78 ppb for Aroclor 1242 and 1254, respectively. This result
24 will help in understanding the toxicological and epidemiological impact of exposure to PCBs in
25 humans.

26 1.0 Introduction

27 Many electrical equipment manufacturing workers in the United States were exposed to
28 polychlorinated biphenyls (PCBs) before their use was banned in 1977. The National Institute
29 for Occupational Safety and Health (NIOSH) is conducting epidemiologic studies of the possible
30 health consequences of occupational exposure to PCBs at three capacitor manufacturing plants
31 (Prince et al., 2006; Rocheleau et al 2011; Ruder et al., 2006; Silver et al., 2009; Steenland et al.,
32 2006), using job-exposure matrices as a surrogate for PCB body burden.

33

34 The PCB body burden (dose levels) over time depends upon toxicokinetics, which includes
35 elimination half-lives (Shirai and Kissel, 1996). Intrinsic human elimination half-lives for PCBs
36 were 10-15 years in a recent study (Ritter et al 2011), derived from cross-sectional biomonitoring
37 data. In humans with occupational exposure to PCBs, several studies have provided estimates for
38 PCB half-life varying from < 1 year to 71 years (Steele et al., 1986; Phillips et al., 1989; Taylor
39 and Lawrence, 1992; Wolff et al., 1992, Seegal et al., 2011). These previous half-life estimates
40 were usually based on only two measurements. The objectives of the current effort were to
41 develop estimates of the half-lives of commercial PCB mixtures Aroclor 1242 and Aroclor 1254
42 using all available sera from a select group of workers from one of the three plants, to consider
43 the role of high initial body burden and gender on the half-life estimates, and to compare the
44 results with other published half-life estimates based on occupational exposure. The estimates
45 were adjusted for PCB background levels (Hopf et al 2009). This is the only study that
46 incorporates four PCB blood measurements over time, allowing us to explore PCB elimination
47 rates.

48

49

50 2.0 Background

51 Shirai and Kissel (1996) reviewed fourteen studies of humans with occupational, accidental, or
52 experimental exposure to PCBs and concluded that very short (i.e., < 1 year) and very long (i.e.,
53 > 10 years) half-lives were probably unlikely. The exponential decay model, assuming first-
54 order kinetics, is given by

$$55 \quad X(t) = X(t_0) e^{-\lambda(t-t_0)}$$

56 where $X(t)$ is the concentration in the compartment at time t , $X(t_0)$ is the unknown initial
57 concentration at time t_0 , and λ is the elimination constant which has units of time^{-1} . The half-life,
58 $t_{1/2}$, is defined as the length of time after which the initial concentration of the chemical is
59 reduced by half, and is equal to the natural logarithm of 2 divided by the elimination constant, or
60 $t_{1/2} = \ln(2) / \lambda$ (Cassarett and Doull, 1986).

61
62 In a controlled pharmacokinetic study, the initial concentration of a chemical in a compartment is
63 known and subsequent concentrations are measured at specific time points. In occupational
64 studies, the initial concentration of a chemical in a compartment after first exposure is usually
65 unknown. Also, exposure typically is chronic, not acute, occurring at different rates over
66 different periods of time. However, measurements taken after exposure is known to have ceased
67 can be used to estimate the half-life for elimination of the chemical from the sera compartment.

68
69 Estimating the half-life of PCBs in the body using sera from exposed workers is complicated;
70 occupational exposure to PCBs was generally to commercial PCB products comprised of varying
71 mixtures of some of the 209 PCB congeners. Different methods exist for quantifying the level of
72 PCBs in sera (Lawton et al., 1985a). Ideally, congener-specific serum PCB levels would be

73 measured. However, in the past, results were typically either quantified using an “Aroclor
74 standard” by summing the heights of selected peaks on the gas chromatogram (GC) which
75 correlated with hallmark peaks in a specific Aroclor, or quantified as lower- or higher-
76 chlorinated PCBs (LPCBs or HPCBs) based on the sum of the GC peaks that occurred before or
77 after the retention time of p,p'-dichlorodiphenyldichloroethylene (DDE), universally detected in
78 sera from people in the industrialized world. The two methods of quantifying PCBs in sera are
79 related, with 93% of Aroclor 1242 being LPCBs and 96% of Aroclor 1260 being HPCBs
80 (Lawton et al., 1985b). The range of chlorination of the Aroclors in sera was determined to be
81 Aroclor 1016: 2-5 chlorines, Aroclor 1242: 2-6 chlorines, Aroclor 1254: 4-7 chlorines, and
82 Aroclor 1260: 4-8 chlorines (Lawton et al., 1985b).

83
84 In addition to degree of chlorination, several other factors are considered to be related to the half-
85 life of PCBs in humans. Wolff et al. (1992) found PCBs in serum from workers (N=60) in jobs
86 with high and direct PCB exposure had shorter half-lives for lower chlorinated PCBs than PCBs
87 in serum from workers (N=105) in jobs with low and indirect PCB exposure (4.8 versus 17
88 years, respectively). A follow-up study of some of these workers (N=45) 28 years later (Seegal
89 et al., 2011), showed somewhat longer half-lives than Wolff et al. (1992) had, but showed the
90 same trend with respect to high initial PCB body burden: half-life estimates for lower chlorinated
91 PCBs were 13.5 and 7.3 years and for higher chlorinated PCBs were 32.6 and 12 years for low
92 and high exposed workers, respectively. Factors complicating the estimation of PCB half-life
93 include percent body fat, laboratory measurement error (Caudill et al., 1992), the time interval
94 between measurements (Caudill et al., 1992), and continuing low-level exposure to PCBs (Shirai
95 and Kissel, 1996), such as background levels of exposure (Michalek et al., 1998).

96
97 Different statistical methods have been proposed for determining the half-life of a substance in
98 humans from an exposed population. The choice of method often depends on the number of
99 participants and the number of measurements available for each participant over time. Steele et
100 al. (1986) used linear regression to estimate the half-lives of PCBs in the body using sera
101 quantified as Aroclors 1242 and 1260. Five capacitor manufacturing workers at one of the
102 NIOSH cohort plants, selected because of their high probability of PCB exposure, provided sera
103 at two draws separated by 84 months. The analysis produced half-life estimates of 2.0 years for
104 Aroclor 1242, 27.6 years for Aroclor 1260, and 11.5 years for total serum PCBs. The median
105 technique was developed by Phillips et al. (1989) to estimate the half-lives of Aroclors 1242 and
106 1254 for 60 former capacitor manufacturing workers (at the same NIOSH cohort plant) with two
107 serum draws separated by 100 months. Phillips et al. reported half-life estimates of 2.6 years for
108 Aroclor 1242 and 4.8 years for Aroclor 1254. In addition, they observed a decreasing trend in
109 half-life based on initial concentration of PCBs in 1977, although Shirai and Kissel (1996)
110 showed that this was likely due to confounding by continuing exposure to PCBs. Table 1 gives
111 an overview of previous half-life estimates from US occupational exposed populations and type
112 of statistical methods used to derive these half-lives.

113
114 Lawton et al. (1985b) initiated a research study in 1976 to study the possible health effects of
115 PCB exposure in workers at another capacitor manufacturing plant (also in the NIOSH cohort)
116 with two facilities in upstate New York. Aroclor 1254 was used at this plant from 1946-1954,
117 Aroclor 1242 from 1954-1971, and Aroclor 1016 from 1971-1977 (Lawton et al., 1985b). In
118 1976, 194 employees, selected because their jobs “required direct contact with PCB in zones of

119 high air concentration, were in the immediate periphery of the high exposure zone, or had high
120 but intermittent exposure”, underwent examinations that included the collection of blood sera
121 from most (n=191). This first examination was approximately one year prior to the termination
122 of PCB use at the plant. Serum draws were repeated in 1979, 1983, and 1988 for subsets of the
123 191 participants. Taylor et al. (1992) used measured serum PCB levels from 148 of the workers
124 who provided sera in both 1979 and 1983 to produce half-life estimates of 1.8 years (95%
125 confidence interval (CI) =1.7 – 1.9) for Aroclor 1242, 3.3 years (95% CI=3.0 – 3.8) for Aroclor
126 1254, and 4.1 years (95% CI=3.6 – 4.7) for Aroclor 1260.

127

128 **3.0 Materials and Methods**

129 The basis for the Aroclor half-life estimates were the Aroclor 1242, 1254, and 1260 serum levels
130 calculated by Lawton et al. (1985). According to study plant records, the use of PCBs in the two
131 facilities ended 30 June 1977. Time intervals from last exposure were measured from that date.
132 Specific dates of the serum draws were not known, but estimated as 15 March 1976, 15
133 November 1979, 15 November 1983, and 1 November 1988 since it is known that PCBs were
134 “still in use during the first 1.3 years after the first examination” (Brown et al., 1989); the second
135 serum draw was in November 1979 (Brown et al., 1984); the third serum draw was 48 months
136 after the second (Taylor et al., 1992); and the fourth serum draw occurred in 1988.

137

138 A majority of the 191 participants in the Lawton study provided sera at four time points
139 (122/194, 63%). Thirty-five participants provided sera at three time points, 19 at two, 15 at one,
140 and three did not provide sera at any of the time points. Therefore, our statistical analysis was
141 performed using results of 191 workers. PCB serum levels were quantified for 185 participants

142 in 1976, 173 in 1979, 150 in 1983, and 138 in 1989. Most participants were male (152/194,
143 78%).

144

145 The methods for quantifying PCB levels (packed column GC with electron capture detector) in
146 the serum have been described (Lawton et al., 1985a). Aroclor standards were used to calculate
147 PCB levels in terms of “Aroclor 1242” and “Aroclor 1254”. Serum PCB levels were quantified
148 by summing peak heights with relative retention times of 37, 70, and 84 as Aroclor 1242 and
149 with relative retention times of 125, 146, 160, and 184, as described in Lawton et al (1985a) as
150 Aroclor 1254 (Brown et al., 1989). (Peak 184 differed from the relative retention time of 174
151 described in the Webb-McCall method (Webb and McCall, 1973).

152

153 Although PCB exposure was ongoing at the time of the first serum measurement, it might be
154 possible to use data from the 1976 serum draw to estimate the half-life for Aroclor 1254 (Brown
155 et al., 1989) since Aroclor 1254 was only used from 1946-1954 at the study plant (Lawton et al.,
156 1985b). Other than gender, information on factors known to affect half-life such as age and
157 percent body fat was unavailable. All statistical analyses were performed using SAS 9 Software
158 (SAS Institute Inc., Cary, NC).

159

160 Background PCB levels might contribute to the length of the half-life estimates; therefore an
161 adjustment for PCB background levels for the years 1976, 1979, 1983, and 1988 was needed.
162 No national statistically based cross-sectional data concerning historical serum PCB levels exist
163 for the U.S. population by year. Therefore, we estimated the background PCB serum levels for

164 these four time points based on the scientific literature (Hopf et al., 2009). The background PCB
165 levels were estimated to follow negative exponential "die away" curves;

166 • for Aroclor 1242; $\text{corr_pcb} = \text{pcb} - 4.18 \cdot \exp(-0.088 \cdot (\text{year} - 1977))$;

167 • for Aroclor 1254; $\text{corr_pcb} = \text{pcb} - 8.5788 \cdot \exp(-0.0569 \cdot (\text{year} - 1977))$;

168 where corr_pcb represents the serum PCB levels (ppb) corrected for background, and pcb is the
169 uncorrected values. Adjustments for PCBs background serum levels were performed by
170 subtracting the estimated background population serum PCB concentrations from the measured
171 serum PCB concentrations prior to log transformation.

172
173 Quantile-quantile plots of natural-log-transformed serum PCB levels ($\ln(\text{PCB})$) versus standard
174 normal quantiles indicated that the data were lognormally distributed (not shown). Figures 1 and
175 2 depict the individual profiles of the log-transformed serum PCB levels over time, for Aroclors
176 1242 and 1254, respectively. Vertical reference lines indicate the times of the serum draws
177 relative to the end of PCB use, and average trend lines were fit using a smoothing routine for
178 females and males. The quadratic term for time was statistically significant for fitting a linear
179 model for all years, indicating that the assumptions of a first-order kinetic model were violated.
180 From the graphs it was apparent that the decrease in earlier years was faster than in later years.
181 This bi-phasic elimination was consistent with elimination patterns from high initial body burden
182 of other chlorinated persistent chemicals such as TCDD (Aylward et al. 2005). Therefore, a
183 linear spline model with a single knot (Keele 2008; Altshuler 1981) approach was used to
184 demonstrate that there were two slopes underlying the die-away curve. This model fit the data
185 well; a linear equation was fitted for the 1976 and 1979 data (Equation A), and a second linear
186 equation was used to fit the 1983 and 1988 data (Equation B) using PROC MIXED. The equality

187 of the slopes estimated over the two time periods was tested by analyzing all the data in a single
188 model which included the interaction between periods with slope. The dependent variables were
189 the natural log transformed PCB Aroclors $\ln(\text{PCB})$.

190

191 The point (transition point) where Equation A and Equation B intersected was estimated by
192 determining the year during which the two regression equations for equations A and B provided
193 the same estimate for PCB concentrations. Other parameters besides background PCB levels
194 affecting elimination such as additional elimination mechanisms (PCB fecal elimination of
195 unchanged compound through lipid partitioning into the large intestine) were unknown and could
196 not be included in the model; hence our model estimates half-life elimination rates based on
197 PCBs (not metabolites) circulating in the blood. The transition point indicating a possible change
198 in elimination rate from rapid to slow was calculated.

199

200 **4.0 Results**

201 Aroclor 1242 quantified measurements increased in five participants from 1976 to 1979, in four
202 participants from 1979 to 1983, and in 32 participants from 1983 to 1988. Likewise, Aroclor
203 1254 quantified measurements increased in 49 participants from 1976 to 1979, in 16 participants
204 from 1979 to 1983, and in 50 participants from 1983 to 1988.

205

206 Detailed work histories, available for 192 of the 194 participants, described 2,684 years of
207 employment at the study plant during the era of PCB exposure (January 1, 1946 – June 30,
208 1977). The median year first employed was 1965 (range 1946 – 1974) and the median duration
209 of employment was 11 years (range 1 – 30 years).

210

211 Summary statistics for the measured serum PCB levels, quantified as Aroclors 1242 and 1254 in
212 parts per billion (ppb) with and without corrections for background serum PCB levels, are
213 provided in Table 2. Measured serum PCB levels were highly variable within a given year. The
214 difference between corrected and uncorrected serum PCB levels was minimal in earlier years due
215 to the high serum PCB levels (e.g. 1976: GM was 1,521 ppb) compared to the value used to
216 adjust for background levels.

217

218 The year Equation A and Equation B intersected (transition point) for Aroclor 1242 was 1980
219 and for Aroclor 1254, 1982. We did not find a statistical significant difference in half-life
220 estimates between genders for Aroclor 1254. This was also true for Aroclor 1242 in later years
221 (Equation B). However, the Aroclor 1242 half-life estimate for equation A (1976-1979) was
222 significantly longer in females (half-life of 2.15 years, 95% confidence interval [C.I.] 1.7 – 2.9
223 years) as compared to males (1.7 years, 95% C.I. 1.4 – 2.2 years, $t=2.21$, $p<0.03$).

224

225 The transition point concentration for Aroclor 1242 and 1254 were 138.57 and 34.78 ppb,
226 respectively. The elimination kinetics of PCBs were concentration dependent with faster rates
227 observed at higher concentrations (>138.57 ppb for Aroclor 1242 and >34.78 ppb for Aroclor
228 1254 ppb) and the transition to slower rates occurring below this concentration.

229

230 Results of the repeated measures regression models and subsequent half-life estimates are
231 provided in Table 3. In the linear spline model with a single knot, the first slope using the first
232 two serum draws (Equation A) produced an estimated half-life of 1.74 years for Aroclor 1242

233 (95% CI = 1.60 – 1.89 years) and 6.01 years for Aroclor 1254 (95% CI = 4.53 – 8.93 years).
234 Using the last two serum draws (Equation B) to model the second slope produced an estimated
235 half-life of 21.83 years for Aroclor 1242 (95% CI = 16.92 – 30.76 years) and 133.33 years for
236 Aroclor 1254 (95% CI = 52.88 - ∞ years). The slopes estimated for the two time periods were
237 significantly different ($p < 0.0001$).

238
239 We compared the geometric means (cGM) of predicted values of Aroclor 1242 with actual cGM
240 for 1976 (predicted 1503: actual 1528), 1979 (predicted 274: actual 280), 1983 (predicted 115:
241 actual 125), and 1988 (predicted 91: actual 92); and for Aroclor 1254: 1976 (predicted 78: actual
242 85), 1979 (predicted 48: actual 55); 1983 (predicted 28: actual 35), and 1988 (predicted 27:
243 actual 32).

244

245 **5.0 Discussion**

246 Estimates of the half-lives of PCBs were based on sera drawn from the same individuals at up to
247 four time points. The half-life, defined as the change in concentration in the body over time is
248 the net result of elimination from the body, changes in the body composition, and intake from the
249 environment. Factors affecting elimination are age, smoking, initial body burden, body fat, and
250 gender (Milbrath et al 2009). Although the gender of each participant was known, age and body
251 mass index data were not available; therefore, it was not possible to adjust for covariates other
252 than gender.

253

254 Half-life estimates for sera from female participants were generally longer than half-life
255 estimates for sera from male participants, although the gender difference was only statistically

256 significant for Aroclor 1242 in the earlier years (equation A). This gender difference in half-life
257 estimates was also seen in Seegal et al., (2011) not only in lower but also higher chlorinated
258 PCBs. PCBs are known to be stored in adipose tissue, therefore half-life estimates are
259 potentially confounded by percent body fat in addition to the rate of PCB migration to the blood
260 (Brown, 1994) or hormonal differences (Kang et al., 2008; Cerna et al., 2008). No clear
261 explanations for this gender-related difference exist, and further investigation is needed.

262
263 High initial PCB body-burden showed a concentration-dependent biphasic elimination rate,
264 which has been identified in related compounds such as 2,3,7,8-tetrachloro-p-dibenzo-dioxin
265 (TCDD) and penta-chlorodibenzofuran (PeCDF) in cases of acute poisoning (Abraham et al
266 2002), Seveso incident (Aylward et al 2005; Michalek et al 2002) in children (Kerger et al 2006),
267 Yusho and Yu-Cheng rice oil poisoning (Leung et al 2007; Ryan et al 1993), but has until now
268 not been reported in workers with chronic high exposures. This non-linear behavior might be due
269 to possible enzyme induction similarly to that seen in TCDD and pentaCDF, as enzyme
270 induction has been observed previously in animals exposed to PCBs (Emond et al, 2005).

271
272 Not adjusting for background PCB levels did not have an impact on equation A (half-lives not
273 corrected for background levels: Aroclor 1242: 1.75 years and Aroclor 1254: 6.8 years). The
274 half-life estimates for uncorrected serum PCB levels using equation B were shortened; giving
275 Aroclor 1242 an half-life of 20.4 years and statistically significantly shortened half-life for
276 Aroclor 1254 of 69.5 years. Since most of these individuals continued to live in the vicinity of
277 the plant they would have an ongoing environmental exposure as would eating contaminated fish

278 in the 1980s. Accounting for background PCB levels will give a more realistic estimate of the
279 half-life.

280
281 Serum levels were reduced by approximately 90% and 50% between the first and third serum
282 draws for Aroclors 1242 and 1254, respectively, but increased between the third and fourth
283 serum draws for 23% and 36% of the participants. By the fourth serum draw, serum PCB levels
284 had fallen to much lower levels and were possibly approaching the levels of those in the general
285 population who have somewhat elevated environmental exposures. The reasons for the increases
286 in serum PCB levels between consecutive serum draws seen in some workers are not known.
287 Possible explanations are de-chlorination of congeners to lower chlorinated PCB; where
288 particular congeners would be quantified as Aroclor 1254 in earlier serum draws, and as Aroclor
289 1242 in later serum draws. Continued occupational exposures were possible for those workers
290 who dismantled the plant, and as mentioned above living in the vicinity could give higher
291 environmental exposures. Other factors that could lead to increases in PCBs in these workers are
292 laboratory measurement error, increased release of PCBs into the blood from body fat storage, or
293 a combination of factors. These factors could lead to unrealistic long half-life estimates.

294
295 Dioxin-like (DL) PCBs (PCB77, PCB 81, PCB 126, PCB 169, PCB 105, PCB 114, PCB 118,
296 PCB 123, PCB 156, PCB 157, PCB 167, PCB 89) are tetra-, penta-, and hexa-chlorinated
297 congeners. A complete PCB congener distribution of Aroclor mixtures has been published
298 (Frame et al 1996), and the weight% of DL-PCB congeners for Aroclor 1016, Aroclor 1242, and
299 Aroclor 1254 were 0%, 1.95%, and 23.58%, respectively. Therefore workers in the early time
300 period exposed to Aroclor 1254 (before the 1960s) had higher DL-PCB exposures compared to

301 workers who were only exposed to Aroclor 1242 (~1960-1970) and Aroclor 1016 (in the 1970s)
302 used in later time periods. DL-PCBs in workers' blood samples can be estimated from Seegal et
303 al 2011; they re-analyzed stored blood samples previously determined as lower (LPCBs; peaks
304 eluding before DDE in the chromatogram) and higher (HPCBs; peaks eluding after DDE in the
305 chromatogram) PCBs, and found four DL-PCBs congeners (118, 105, 167, 156); all present in
306 peaks quantified as HPCBs.

307
308 Shirai and Kessel (1996) reasoned that half-lives longer than 10 years were probably the result of
309 confounding by additional exposure. Wolff et al. (1992), on the other hand, observed long half-
310 lives which they attributed to the presence of congeners with relatively longer half-lives in the
311 sera compared to the distribution of congeners in the Aroclor mixtures. The explanation we can
312 offer is that elimination of PCB congeners with shorter half-lives (generally, lower chlorinated
313 biphenyls) from high initial PCB serum levels is estimated with Equation A, while Equation B is
314 an estimate of the elimination of PCB congeners with long half-life as described by Wolff et al
315 (1992) with continuous exposure to PCB background levels as described by Shirai and Kessel
316 (1996). Researchers who have continuously monitored PeCDF in a group of Yusho patients,
317 poisoned by PCB contaminated rice bran oil, have recently reported that these patients maintain
318 a high level resulting in an infinite half-life (Matsumoto et al 2009). The authors suggested that a
319 more complicated model to explain excretion in humans were needed.

320
321 One of the strengths of this study was that PCB measurements were available at up to four time
322 points per participant, and a linear spline model with a single knot was used to estimate PCB
323 half-lives. Advantages of the linear spline model with a single knot include generalizability to

324 any number of repeated measures, the ability to handle varying numbers of repeated measures
325 per participant, and the ability to adjust the half-life estimate for covariates such as gender by
326 adding the appropriate terms and interactions to the model.

327
328 Unlike all previous half-life estimates reported in the scientific literature, ours is based on serum
329 draws from four time points, which allowed us to explore more than one linear regression PCB
330 elimination rate. A single linear regression using all four time points did not achieve as good a
331 fit as did the linear spline model with a single knot. We did not try more than a single knot as
332 based on the data; the linear slope for decline appeared much steeper between the first 2
333 occasions than the latter two. This bi-phasic decay was also observed by Brown and Lawton
334 (2001) who tried to fit a pseudo-first order elimination to their studies' three serum draws. Other
335 studies (Phillips et al., 1989; Taylor and Lawrence, 1992; Brown et al., 1989; Wolff et al., 1992)
336 estimated half-lives based on serum draws at only two time points, which resulted in shorter half-
337 lives (Table 1). The half-life estimates using the linear spline model with a single knot were
338 somewhat shorter for Equation A and longer for Equation B than estimates previously published,
339 because it incorporates high initial PCB body burden (Equation A) and low body burden
340 (Equation B). The equation A estimated half-life of 1.8 years for Aroclor 1242 was 31% shorter
341 than the 2.6-year estimate by Phillips (1989), 81% shorter than the 9.6-year estimate by Seegal et
342 al. (2011), but the same as the estimate by Taylor et al. (1992). Equation B estimated an half-life
343 of 21.8 years for Aroclor 1242, 2.3, 7.4, and 11.1 times longer than the estimates by Seegal et al.
344 (2011), Phillips (1989), and Taylor et al. (1992), respectively. Likewise, Equation A estimated a
345 half-life of 6.01 years for Aroclor 1254, which was 42 and 106% longer than the estimates by
346 Phillips (1989) and Taylor et al. (1992), respectively; and 90 and 62% shorter than the estimates

347 by Wolff et al (1992) and Seegal et al (2011). Equation B estimated half-life of 133.33 years for
348 Aroclor 1254 was 27, 40, 1, and 7.5 times longer than estimates by Phillips (1989), Taylor et al.
349 (1992), Wolff et al. (1992), and Seegal et al. (2011), respectively. The half-life estimates using
350 the linear spline model with a single knot were consistent with elimination rates computed by
351 Phillips et al., 1989; Taylor and Lawrence, 1992; Brown et al., 1989 for the fast elimination rate
352 (Equation A) for a high internal dose, and by Wolff et al 1992, Shirai and Kissel 1996, and
353 Seegal et al. 2011 for the slow elimination rates (Equation B) for a low internal dose approaching
354 background PCB levels.

355
356 Major limitations of this study include not being able to estimate PCB congener-specific half-
357 lives because congener-specific serum data were not available. The PCB half-life estimates
358 would have improved if we could have adjusted for body mass index and age that are known to
359 affect PCBs half-lives. Strengths of these half-life estimates include a relatively long 13-year
360 sampling period, a large study population (191 participants), one to four serum draws per
361 participants, and three sampling points after occupational exposure ended. In addition, these
362 half-life estimates are for individuals with high initial body burdens, which we show here result
363 in concentration-dependent PCB half-lives. Attempts to back-calculate body burden in highly
364 exposed workers based on assumption of uniform half-lives will greatly underestimate dose and
365 overestimate potency as shown for TCDD (Aylward et al 2005).

366

367 **6.0 Conclusion**

368 Our PCB half-life estimates using the linear spline model with a single knot take into account
369 high initial body burden, ongoing environmental exposure, low serum levels, and congeners with

370 very long half-lives. The estimated half-lives during a period of high internal dose were 1.74
371 years for Aroclor 1242 and 6.01 years for Aroclor 1254, modeling elimination using sera from
372 the first two serum draws. Half-lives during a period of low internal dose were estimated to be
373 21.83 years and 133.33 years for Aroclor 1242 and Aroclor 1254, respectively, using the final
374 two serum draws. The transition point for Aroclor 1242 was 138.57 ppb and for Aroclor 1254
375 was 34.78 ppb. The high internal dose estimates are in general agreement with the half-life
376 estimates reported in Phillips et al. (1989) and Brown and Lawton (2001), and the low dose
377 estimates are in agreement with Wolff et al. 1992 and Seegal et al. 2011. These half-life
378 estimates may aid in assessing PCB exposures retrospectively and reconstructing PCB dose
379 estimates for persons on whom biological monitoring was performed only once, which may in
380 turn help in understanding the toxicological and epidemiological impact of exposure to PCBs in
381 humans.

382

383 Acknowledgement: We thank all external, internal, and tri-partite reviewers for carefully
384 reviewing the manuscript.

385

386

387 **References**

- 388 Abraham, K., Geusau, A., Tosun, Y., Helge, H., Bauer, S., Brockmoller, J., 2002. Severe 2,3,7,8-
389 tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic
390 cytochrome P450 1A2 induction. *Clin. Pharmacol. Ther.* 72, 163-174.
391
- 392 Altshuler, B., 1981. Modeling of dose-response relationships. *Environ. Health. Perspect.* 42, 23-
393 7.
394
- 395 Aylward, L.L., Brunet, R.C., Carrier, G., Hays, S.M., Cushing, C.A., Needham, L.L., Patterson,
396 D.G. Jr., Gerthoux, P.M., Brambilla, P., Mocarelli, P., 2005. Concentration-dependent TCDD
397 elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults
398 from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort. *J.*
399 *Expo. Anal. Environ. Epidemiol.* 15, 51-65.
400
- 401 Brown, D.P., 1987. Mortality of workers exposed to polychlorinated biphenyls-an update. *Arch.*
402 *Environ. Health.* 42, 333-339.
403
- 404 Brown, J.F. Jr., Lawton, R.W., 1984. Polychlorinated biphenyl (PCB) partitioning between
405 adipose tissue and serum. *Bull. Environ. Contam. Toxicol.* 33, 277-80.
406
- 407 Brown, J.F. Jr., Lawton, R.W., Ross, M.R., Feingold, J., Wagner, R.E., Hamilton, S.B., 1989.
408 Persistence of PCB congeners in capacitor workers and yusho patients. *Chemosphere.* 19, 829-
409 34.
410
- 411 Brown, J.F. Jr., 1994. Determination of PCB metabolic, excretion, and accumulation rates for
412 use as indicators of biological response and relative risk. *Environ. Sci. Technol.* 28, 2295-305.
413
- 414 Brown, J.F., Lawton, R.W., 2001. Factors controlling the distribution and levels of PCBs after
415 occupational exposure. In Robertson and Hansen eds. *PCBs. The University Press of Kentucky,*
416 103-109.
417
- 418 Caudill, S.P., Pirkle, J.L., Michalek, J.E., 1992. Effects of measurement error on estimating
419 biological half-life. *J. Exp. Anal. Environ. Epi.* 2, 463-476.
420
- 421 Cerna, M., Maly, M., Grabic, R., Batariova, A., Smid, J., Benes, B. 2008. Serum concentrations
422 of indicator PCB congeners in the Czech adult population. *Chemosphere* 72, 1124-1131.
423
- 424 Emond, C., Charbonneau, M., Krishnan, K., 2005. Physiologically based modeling of the
425 accumulation in plasma and tissue lipids of a mixture of PCB congeners in female sprague-
426 dawley rats. *J. Toxicol. Environ. Health A.* 68, 1393-1412.
427
- 428 Frame, G.M., Cochran, J.W., Bowadt, S.S., 1996. Complete PCB Congener Distributions for 17
429 Aroclor Mixtures Determined by 3 HRGC Systems Optimized for Comprehensive, Quantitative,
430 Congener-Specific Analysis. *J. High Resol. Chromatogr.* 19, 657-668.
431

- 432 Hopf, N.B., Ruder, A.M., Succop, P., 2009. Background levels of polychlorinated biphenyls in
433 the U.S. population. *Sci. Tot. Environ.* 407, 6109-6119.
434
- 435 Kang, J.H., Park, H., Chang, Y.S., Choi, J.W., 2008. Distribution of organochlorine pesticides
436 (OCPs) and polychlorinated biphenyls (PCBs) in human serum from urban areas in Korea.
437 *Chemosphere.* 73, 1625-1631.
438
- 439 Keele, L. J. 2008. *Semiparametric Regression for the Social Sciences.* John Wiley & Sons, Ltd,
440 p. 49.
441
- 442 Kerger, B.D., Leung, H.W., Scott, P., Paustenbach, D.J., Needham, L.L., Patterson, D.G. Jr,
443 Gerthoux, P.M., Mocarelli, P., 2006. Age-and concentration-dependent elimination half-life of
444 2,3,7,8-tetrachlorodibenzo-p-dioxin in Seveso children. *Environ. Health. Perspec.* 114, 1596-
445 1602.
446
- 447 Lawton, R.W., Brown, J.F. Jr., Ross, M.R., Feingold, J., 1985a. Comparability and precision of
448 serum PCB measurements. *Arch. Environ. Health.* 40, 29-37.
449
- 450 Lawton, R.W., Ross, M.R., Feingold, J., Brown, J.F. Jr., 1985b. Effects of PCB exposure on
451 biochemical and hematological findings in capacitor workers. *Environ. Health. Perspec.* 60,
452 165-184.
453
- 454 Leung, H.W., Kerger, B.D., Paustenbach, D.J., Ryan, J.J., Masuda, Y., 2007. Concentration and
455 age-dependent elimination kinetics of polychlorinated dibenzofurans in Yucheng and Yusho
456 patients. *Toxicol. Ind. Health.* 7, 493-501.
457
- 458 Matsumoto, S., Akahane, M., Kanagawa, Y., Koike, S., Yoshimura, T., Mitoma, C., Shibata, S.,
459 Uchi, H., Furue, M., Imamura, T., 2009. Variation in half-life of penta-chlorodibenzofuran
460 (PeCDF) blood level among Yusho patients. *Chemosphere.* 77, 658-662.
461
- 462 Michalek, J.E., Pirkle, J.L., Needham, L.L., Patterson, D.G. Jr, Caudill, S.P., Tripathi, R.C.,
463 Mocarelli, P., 2002. Pharmacokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in Seveso adults
464 and veterans of operation Ranch Hand. *J. Expo. Anal. Environ. Epidemiol.* 12, 44-53.
465
- 466 Michalek, J.E., Tripathi, R.C., Kulkarni, P.M., Gupta, P.L., Selvavel, K. 1998. Correction for
467 bias introduced by truncation in pharmacokinetic studies of environmental contaminants.
468 *Environmetrics.* 9, 165-174.
469
- 470 Milbrath, O.M., Wenger, Y., Chang, C.W., Emond, C., Garabrant, D., Gillespie, B.W., Jolliet,
471 O., 2009. half-lives of dioxins, furans, and polychlorinated biphenyls as a function of age, body
472 fat, smoking status and breast-feeding. *Environ. Health. Perspec.* 117, 417-425.
473
- 474 Phillips, D.L., 1989. Propagation of error and bias in half-life estimates based on two
475 measurements. *Arch. Environ. Contam. Toxicol.* 18, 508-514.
476

- 477 Phillips, D.L., Smith, A.B., Burse, V.W., Steele, G.K., Needham, L.L., Hannon, W.H., 1989.
478 Half-life of polychlorinated biphenyls in occupationally-exposed workers. *Arch. Environ.*
479 *Health.* 44, 351-354.
480
- 481 Prince, M.M., Ruder, A.M., Hein, M.J., Waters, M.A., Whelan, E.A., Nilsen, N., Ward, E.M.,
482 Schnorr, T.M., Laber, P.A., Davis-King, K.E., 2006. Mortality and exposure response among
483 14,458 electrical capacitor manufacturing workers exposed to polychlorinated biphenyls (PCBs).
484 *Environ. Health. Perspec.* 114, 1508-1514.
485
- 486 Ritter, R., Scheringer, M., MacLeod, M., Moeckel, C., Jones, K.C., Hungerbühler, K., 2011.
487 Intrinsic human elimination half-lives of polychlorinated biphenyls derived from the temporal
488 evolution of cross-sectional biomonitoring data from the United Kingdom. *Environ. Health.*
489 *Perspec.* 119, 225-231.
490
- 491 Rocheleau CM, Bertke SJ, Deddens JA, Ruder AM, Lawson CC, Waters MA, et al. 2011.
492 Maternal exposure to polychlorinated biphenyls and the secondary sex ratio: an occupational
493 cohort study. *Environ Health* 10: 20.
494
- 495 Ruder, A.M., Hein, M.J., Nilsen, N., Waters, M.A., Laber, P., Davis-King, K., Prince MM,
496 Whelan E., 2006. Mortality among workers exposed to polychlorinated biphenyls (PCBs) in an
497 electrical capacitor manufacturing plant in Indiana: an update. *Environ. Health. Perspec.* 114, 18-
498 23.
499
- 500 Ryan, J.J., Levesque, D., Panopio, L.G., Sun, W.F., Masuda, Y., Kuroki, H., 1993. Elimination
501 of polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) from human
502 blood in the Yusho and Yu-Cheng rice oil poisonings. *Arch. Environ. Contam. Toxicol.* 24, 504-
503 512.
504
- 505 SAS Institute Inc., SAS/STAT 9.1 User's Guide. Cary, NC: SAS Institute Inc., 2004.
506
- 507 Seegal, R.F., Fitzgerald, E.F., Hills, E.A., Wolff, M.S., Haase, R.F., Todd, A.C., Parsons, P.,
508 Molho, E.S., Higgins, D.S., Factor, S.A., Marek, K.L., Seibyl, J.P., Jennings, D.L., McCaffrey,
509 R.J., 2011. Estimating the half-lives of PCB congeners in former capacitor workers measured
510 over a 28-year interval. *J. Exp. Sci. Environ. Epi.* 21, 234-246.
511
- 512 Shirai, J.H., Kissel, J.C., 1996. Uncertainty in estimated half-lives of PCBs in humans: impact
513 on exposure assessment. *Sci. Tot. Environ.* 187, 199-210.
514
- 515 Silver, S.R., Whelan, E.A., Deddens, J.A., Steenland, N.K., Hopf, N.B., Waters, M.A. Ruder,
516 A.M., Prince, M.M., Yong, L.C., Hein, M.J., Ward, E.M., 2009. Occupational exposure to
517 polychlorinated biphenyls and risk of breast cancer *Environ. Health. Perspect.* 117, 276-282.
518
- 519 Steele, G., Stehr-Green, P., Welty, E., 1986. Estimates of the biologic half-life of polychlorinated
520 biphenyls in human serum. *New. Engl. J. Med.* 314, 926-927.
521

- 522 Steenland, K., Hein, M.J., Cassinelli, R.T. 2nd, Prince, M.M., Nilsen, N.B., Whelan, E.A. Waters
523 MA, Ruder AM, Schnorr TM., 2006. Polychlorinated biphenyls and neurodegenerative disease
524 mortality in an occupational cohort. *Epidemiology*. 17, 8-13.
525
- 526 Taylor, P.R., Lawrence, C.E., 1992. Polychlorinated biphenyls: estimated serum half-lives. *Brit.*
527 *J. Ind. Med.* 49, 527-528.
528
- 529 Webb, R.G., McCall, A.C., 1973. Quatitative PCB standards for electron capture gas
530 chromatography. *J. Chrom. Sci.* 11, 366-373.
531
- 532 Wolff MS, Fischbein A, Selikoff IJ. Changes in PCB serum concentrations among capacitor
533 manufacturing workers. *Environ Res* 1992;59:202-16.
534